BR112012026939A2 - método para tratamento de um paciente sofrendo da perda ou debilitação da visão - Google Patents
método para tratamento de um paciente sofrendo da perda ou debilitação da visãoInfo
- Publication number
- BR112012026939A2 BR112012026939A2 BR112012026939A BR112012026939A BR112012026939A2 BR 112012026939 A2 BR112012026939 A2 BR 112012026939A2 BR 112012026939 A BR112012026939 A BR 112012026939A BR 112012026939 A BR112012026939 A BR 112012026939A BR 112012026939 A2 BR112012026939 A2 BR 112012026939A2
- Authority
- BR
- Brazil
- Prior art keywords
- treating
- visual
- impairment
- patient suffering
- vision loss
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
método para tratamento de um paciente sofrendo da perda ou debilitação da visão são descritos aqui regimes terapêuticos para o tratamento ou melhoria de um distúrbio visual associado à deficiência de retinoide endógeno em um indivíduo através da administração de uma quantidade terapeuticamente eficiente de um derivado de retinal sintético ou uma composição farmaceuticamente aceitável compreendendo um derivado de retinalo sintético de acordo com o regime terapêutico que leva à recuperação local de funções visuais, tais como visuais, acuidade visual e sensibilidade retinal, dentre outras.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32576310P | 2010-04-19 | 2010-04-19 | |
US40743610P | 2010-10-27 | 2010-10-27 | |
US201161447611P | 2011-02-28 | 2011-02-28 | |
PCT/IB2011/001294 WO2011132084A2 (en) | 2010-04-19 | 2011-04-19 | Therapeutic regimen and method for treating or ameliorating visual disorders associated with an endogenous retinoid deficiency |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012026939A2 true BR112012026939A2 (pt) | 2016-07-12 |
Family
ID=44788663
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012026939A BR112012026939A2 (pt) | 2010-04-19 | 2011-04-19 | método para tratamento de um paciente sofrendo da perda ou debilitação da visão |
Country Status (18)
Country | Link |
---|---|
US (3) | US9173856B2 (pt) |
EP (1) | EP2563350B1 (pt) |
JP (4) | JP6250389B2 (pt) |
KR (2) | KR101851249B1 (pt) |
CN (2) | CN102939081A (pt) |
AU (3) | AU2011244024B2 (pt) |
BR (1) | BR112012026939A2 (pt) |
CA (1) | CA2796991A1 (pt) |
CL (1) | CL2012002942A1 (pt) |
CO (1) | CO6640227A2 (pt) |
HK (1) | HK1246171A1 (pt) |
IL (1) | IL222567A (pt) |
MX (1) | MX339834B (pt) |
NO (1) | NO20121362A1 (pt) |
NZ (1) | NZ603331A (pt) |
RU (1) | RU2622763C2 (pt) |
SG (2) | SG184971A1 (pt) |
WO (1) | WO2011132084A2 (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011034551A2 (en) | 2009-09-15 | 2011-03-24 | Qlt Inc. | Pharmaceutical formulations comprising 9-cis-retinyl esters in a lipid vehicle |
KR101851249B1 (ko) | 2010-04-19 | 2018-06-20 | 노벨리언 테라퓨틱스 인코포레이티드 | 내인성 레티노이드 결핍과 연관된 시각 장애의 치료 또는 완화를 위한 치료용 조성물, 제형 및 키트 |
NZ629267A (en) * | 2012-03-01 | 2016-11-25 | Quadra Logic Tech Inc | Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency |
WO2015023902A2 (en) * | 2013-08-14 | 2015-02-19 | Qlt Inc. | Therapeutic regimens and methods for improving visual function in visual disorders associated with impaired dark adaptation and/or impaired low luminance vision |
US11845951B2 (en) | 2017-09-29 | 2023-12-19 | Toolgen Incorporated | Gene manipulation for treatment of retinal dysfunction disorder |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3196078A (en) | 1962-01-30 | 1965-07-20 | Ortho Pharma Corp | Process for combating retinits pigmentosa |
US3517067A (en) | 1964-02-11 | 1970-06-23 | Eastman Kodak Co | Syntheses of quaternary phosphonium salts |
DE2300107C2 (de) | 1973-01-03 | 1982-03-11 | Basf Ag, 6700 Ludwigshafen | Vitamin A-Säureanilid-4-carbonsäureäthylester, Verfahren zu seiner Herstellung und diesen enthaltende Zubereitungen |
CH590222A5 (pt) | 1973-08-21 | 1977-07-29 | Hoffmann La Roche | |
US4022913A (en) | 1973-09-13 | 1977-05-10 | Hoffmann-La Roche Inc. | High potency vitamin A compositions |
DE2456959A1 (de) | 1974-12-03 | 1976-06-16 | Basf Ag | 4-(e)- und 4-(z)-7-methyl-9-(2,6,6trimethyl-1-cyclohexen-1-yl)-nona-2,4,6,8tetraencarbonsaeure, ihre derivate und diese enthaltende zubereitungen |
US4532133A (en) | 1983-05-24 | 1985-07-30 | Basf Wyandotte Corporation | Low temperature stable, emulsifiable vitamin A concentrates |
CA1282326C (en) | 1984-12-14 | 1991-04-02 | Paul J. Jarosz | Pharmaceutical composition containing 13-cis vitamin a acid as the active ingredient |
JPS61275266A (ja) | 1985-05-28 | 1986-12-05 | Taisho Pharmaceut Co Ltd | レチノイド誘導体 |
CZ282548B6 (cs) | 1992-01-22 | 1997-08-13 | F. Hoffmann-La Roche Ag | Farmaceutický přípravek |
US5310764A (en) | 1992-05-08 | 1994-05-10 | Steven Baranowitz | Treatment of age related macular degeneration with beta-carotene |
JPH06340525A (ja) | 1993-06-02 | 1994-12-13 | Lion Corp | 安定な低眼刺激性ビタミンa類可溶化点眼剤 |
EP0754046A1 (en) | 1994-04-04 | 1997-01-22 | FREEMAN, William R. | Use of phosphonylmethoxyalkyl nucleosides for the treatment of raised intraocular pressure |
US5425560A (en) | 1994-04-21 | 1995-06-20 | Strattec Security Corporation | Squeeze latch |
RU2106843C1 (ru) | 1994-06-29 | 1998-03-20 | Красноярская государственная медицинская академия | Способ лечения близорукости |
JPH08198746A (ja) | 1995-01-18 | 1996-08-06 | Lion Corp | 可溶化点眼剤 |
US5837728A (en) | 1995-01-27 | 1998-11-17 | Molecular Design International | 9-cis retinoic acid esters and amides and uses thereof |
US5489611A (en) | 1995-02-10 | 1996-02-06 | Warner-Lambert Company | Method for lowering plasma levels of lipoprotein (a) |
US5620970A (en) | 1995-06-05 | 1997-04-15 | Alcon Laboratories, Inc. | Topical ophthalmic carbonic anhydrase inhibitor formulations |
AU6390096A (en) | 1995-07-20 | 1997-02-18 | Pharmacia & Upjohn Company | Stable clear solutions of non-steroidal anti-inflammatory drugs for incorporation into gelatin capsules |
US5716627A (en) | 1996-04-25 | 1998-02-10 | Elizabeth Arden Co., Division Of Conopco, Inc. | Skin care compositions containing fatty acid amides, azoles, and retinol or retinyl ester |
EP0908179A1 (en) | 1997-08-23 | 1999-04-14 | Werner Bollag | Treatment of cell-mediated immune diseases |
ZA989513B (en) | 1997-10-21 | 1999-04-21 | Alcon Lab Inc | Compositions containing histamine H2 agonists and methods of use in treating dry eye |
US6391924B1 (en) | 1997-12-10 | 2002-05-21 | Hampar Karageozian | Taurine derivatives useable in the treatment of ophthalmic disorders |
US6552009B2 (en) | 1998-07-16 | 2003-04-22 | Gentrix Llc | Compositions and methods of treating abnormal cell proliferation |
US6267985B1 (en) | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
US6372463B1 (en) | 1999-05-06 | 2002-04-16 | The President & Fellows Of Harvard College | Mutations in nucleic acid molecules encoding 11-CIS retinol dehydrogenase, the mutated proteins, and uses thereof |
US6300328B1 (en) | 1999-08-06 | 2001-10-09 | Alcon Universal Ltd. | Selective inhibitors of adenosine monophosphate deaminase for the treatment of optic nerve and retinal damage |
US20020028849A1 (en) | 2000-04-18 | 2002-03-07 | Godkin James D. | Use of retinol in assisted-reproduction protocols |
US6696069B2 (en) | 2000-06-30 | 2004-02-24 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Skin care cosmetic compositions containing phosphates and/or sulfates of branched alcohols and/or ethoxylates thereof |
US20040077604A1 (en) | 2001-12-19 | 2004-04-22 | Lenard Lichtenberger | Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providingenhanced therapeutic activity |
JP4210115B2 (ja) | 2001-01-11 | 2009-01-14 | チェビジェン・インコーポレイテッド | 新規レチノール誘導体および製造方法および用途 |
EP1381276A4 (en) | 2001-04-13 | 2005-02-02 | Univ Pennsylvania | METHOD FOR TREATMENT OR DEVELOPMENT SLUDGE DEGRADATION |
ITMI20012366A1 (it) | 2001-11-09 | 2003-05-09 | Farmatron Ltd | Sistemi terapeutici stabilizzati a rilascio immediato e/o modificato per la somministrazione orale di principi attivi e/o eccipienti e/o ali |
US7875728B2 (en) | 2001-11-30 | 2011-01-25 | Valocor Therapeutics, Inc. | Hydrazonopyrazole derivatives and their use as therapeutics |
EP1476147A4 (en) | 2002-01-18 | 2005-03-09 | Tatton Technologies Llc | METHODS OF TREATING VIEW DISORDERS |
US20030215413A1 (en) | 2002-03-22 | 2003-11-20 | L'oreal | Compositions containing stabilized retinoid |
US20040097587A1 (en) | 2002-03-27 | 2004-05-20 | Arbiser Jack L | Compositions and methods of treatment of ulcerating diseases, burns, and related conditions |
US20030228277A1 (en) | 2002-03-29 | 2003-12-11 | Gehlsen Kurt R. | Use of ROM production and release inhibitors to treat and prevent intraocular damage |
JP3854524B2 (ja) * | 2002-04-01 | 2006-12-06 | ピアス株式会社 | 油溶性成分安定化組成物及びその組成物を配合した化粧料、並びに油溶性成分の安定化方法 |
EP1527774A1 (en) | 2003-11-03 | 2005-05-04 | Basilea Pharmaceutica AG | New formulation for retinoid-containing soft gelatin capsules |
AU2004222279B2 (en) * | 2003-03-14 | 2010-01-21 | University Of Washington | Retinoid replacements and opsin agonists and methods for the use thereof |
EP1510133A1 (en) | 2003-09-01 | 2005-03-02 | Belovo S.A., Egg Science & Technology | Balanced oil composition |
EP2412304B1 (en) | 2003-09-04 | 2016-08-03 | The UAB Research Foundation | Method and apparatus for the detection of impaired dark adaptation |
US7706863B2 (en) | 2004-01-21 | 2010-04-27 | University Of Washington | Methods for assessing a physiological state of a mammalian retina |
KR20060135819A (ko) | 2004-02-17 | 2006-12-29 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 황반변성을 포함하는 안과질환의 관리 |
AU2005221283C1 (en) | 2004-03-17 | 2011-02-03 | Lars Michael Larsen | Prevention of retinopathy by inhibition of the visual cycle |
US7951841B2 (en) | 2004-06-18 | 2011-05-31 | University Of Washington | Retinal derivatives and methods for the use thereof for the treatment of visual disorders |
EP1768657B1 (en) * | 2004-06-23 | 2008-08-13 | Sirion Therapeutics, Inc. | Methods and compositions for treating ophthalmic conditions with retinyl derivates |
US20060240098A1 (en) | 2004-07-14 | 2006-10-26 | Aphios Corporation | Formulations for hyperforin-enriched hypericum fractions |
AU2005287343A1 (en) | 2004-08-18 | 2006-03-30 | Sirion Therapeutics, Inc. | Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat opthalmic disorders |
WO2006039551A2 (en) * | 2004-09-30 | 2006-04-13 | The Regents Of The University Of California | Local administration of retinoids to treat deficiencies in dark adaptation |
US20060177392A1 (en) | 2005-02-10 | 2006-08-10 | William Walden | Oil-based composition for acne |
JP2009514890A (ja) | 2005-11-07 | 2009-04-09 | マーティ・ファーマシューティカルズ・インク | テトラヒドロカンナビノールの改良された送達 |
US8202541B2 (en) | 2006-02-07 | 2012-06-19 | U.S. Nutraceuticals, LLC | Dietary supplement composition for blood lipid health |
WO2008013983A2 (en) | 2006-07-27 | 2008-01-31 | University Of Florida Research Foundation, Inc. | Opsin stabilizing compounds and methods of use |
CN107652212B (zh) | 2007-01-15 | 2019-11-15 | 于崇曦 | 维生素a酸类和类维生素a酸化合物的前药 |
US8877809B2 (en) | 2007-09-12 | 2014-11-04 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for treating macular degeneration |
CA2714530C (en) * | 2008-02-11 | 2018-09-25 | University Of Washington | Methods for the treatment and prevention of age-related retinal dysfunction |
WO2011034551A2 (en) | 2009-09-15 | 2011-03-24 | Qlt Inc. | Pharmaceutical formulations comprising 9-cis-retinyl esters in a lipid vehicle |
KR101851249B1 (ko) | 2010-04-19 | 2018-06-20 | 노벨리언 테라퓨틱스 인코포레이티드 | 내인성 레티노이드 결핍과 연관된 시각 장애의 치료 또는 완화를 위한 치료용 조성물, 제형 및 키트 |
NZ629267A (en) | 2012-03-01 | 2016-11-25 | Quadra Logic Tech Inc | Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency |
-
2011
- 2011-04-19 KR KR1020127030132A patent/KR101851249B1/ko active IP Right Grant
- 2011-04-19 CN CN2011800302646A patent/CN102939081A/zh active Pending
- 2011-04-19 US US13/090,215 patent/US9173856B2/en active Active
- 2011-04-19 SG SG2012078143A patent/SG184971A1/en unknown
- 2011-04-19 KR KR1020187010745A patent/KR20180043846A/ko not_active Application Discontinuation
- 2011-04-19 RU RU2012148812A patent/RU2622763C2/ru active
- 2011-04-19 BR BR112012026939A patent/BR112012026939A2/pt not_active Application Discontinuation
- 2011-04-19 EP EP11771664.7A patent/EP2563350B1/en active Active
- 2011-04-19 AU AU2011244024A patent/AU2011244024B2/en not_active Ceased
- 2011-04-19 NZ NZ603331A patent/NZ603331A/en not_active IP Right Cessation
- 2011-04-19 MX MX2012012199A patent/MX339834B/es active IP Right Grant
- 2011-04-19 WO PCT/IB2011/001294 patent/WO2011132084A2/en active Application Filing
- 2011-04-19 SG SG10201507819VA patent/SG10201507819VA/en unknown
- 2011-04-19 CA CA2796991A patent/CA2796991A1/en not_active Abandoned
- 2011-04-19 JP JP2013505568A patent/JP6250389B2/ja active Active
- 2011-04-19 CN CN201710417111.6A patent/CN107308143A/zh active Pending
-
2012
- 2012-10-19 CL CL2012002942A patent/CL2012002942A1/es unknown
- 2012-10-21 IL IL222567A patent/IL222567A/en active IP Right Grant
- 2012-11-19 NO NO20121362A patent/NO20121362A1/no not_active Application Discontinuation
- 2012-11-19 CO CO12208550A patent/CO6640227A2/es not_active Application Discontinuation
-
2013
- 2013-06-25 HK HK18105673.3A patent/HK1246171A1/zh unknown
-
2015
- 2015-09-24 JP JP2015187459A patent/JP2016014047A/ja active Pending
- 2015-10-05 US US14/875,342 patent/US9987245B2/en active Active
-
2016
- 2016-03-04 AU AU2016201432A patent/AU2016201432A1/en not_active Abandoned
-
2017
- 2017-09-29 JP JP2017189573A patent/JP2017222721A/ja active Pending
- 2017-12-03 AU AU2017268684A patent/AU2017268684A1/en not_active Abandoned
-
2018
- 2018-05-01 US US15/968,358 patent/US20190029986A1/en not_active Abandoned
-
2019
- 2019-06-27 JP JP2019120244A patent/JP2019178162A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015027282A2 (pt) | fenfluramina para uso no tratamento de síndrome de dravet | |
BR112015011933A2 (pt) | composições bacterianas sinérgicas e métodos de produção e uso das mesmas | |
BR112014008731A2 (pt) | tratamento de esclerose múltipla com combinação de laquinimode e fingolimode | |
BR112015005048A2 (pt) | métodos para tratar dermatite atópica por administração de antagonista il-4r | |
NI201000105A (es) | Régimen de dosificación asociado con ésteres de paliperidona inyectables de acción prolongada. | |
PE20180260A1 (es) | Metodos y kits para tratar la depresion | |
AR060306A1 (es) | Terapia de combinacion de anticuerpos contra ctla4 | |
IN2014MN00333A (pt) | ||
WO2019006005A3 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA | |
EA201490911A1 (ru) | Способы лечения злокачественных опухолей с использованием пероральных составов аналогов цитидина | |
BR112013000027A2 (pt) | tratamento de distúrbios cognitivos | |
MX336145B (es) | Metodo para el tratamiento de insuficiencia cardiaca cronica. | |
BR112014030404A2 (pt) | proteína de fusão hgh-xten e seu uso no tratamento da deficiência de hormônio do crescimento | |
BR112012026939A2 (pt) | método para tratamento de um paciente sofrendo da perda ou debilitação da visão | |
BR112013004685A2 (pt) | composição e método para reparação e regeneração muscular | |
BR112014021602A2 (pt) | uso, kit e derivado de retinal sintético para melhorar a função visual em distúrbios visuais associados com a deficiência de produção endógena de retinóide | |
EP3818991A3 (en) | Compositions and methods for treating diseases | |
BR112012016543A2 (pt) | Tratamento com vb-201 | |
BR112014009785A8 (pt) | método para tratar ou reduzir efp | |
BRPI0908541B8 (pt) | uso de panax quinquefolius ou uma fração do mesmo na ativação de respostas imunes inatas e adaptativas | |
CO7101244A2 (es) | Fenilimidazopirazoles sustituidos y su uso | |
WO2012063134A3 (en) | Cardiac glycoside analogs in combination with emodin for cancer therapy | |
RU2015116264A (ru) | Композиции и способы лечения сердечной недостаточности у пациентов с диабетом | |
UY34896A (es) | Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina | |
BR112015001859A2 (pt) | tratamento de inflamação utilizando serelaxina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B04C | Request for examination: application reinstated [chapter 4.3 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
B11T | Dismissal of application maintained [chapter 11.20 patent gazette] |